This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.More than 50 drugs with the potential to cause the life threatening arrhythmia torsades de pointes (TdP) are available in the U.S. Patients with heart failure (HF) due to left ventricular (LV) dysfunction are at increased risk for drug-induced TdP, due to undetermined mechanisms. We hypothesize that the increased risk of drug-induced TdP in patients with HF is due to 1) Increased myocardial responsiveness to potassium channel blockade, manifested by altered QT interval pharmacodynamics, and/or 2) Alterations in pharmacokinetics of hepatically metabolized potassium channel blocking agents. Patients with HF and atrial fibrillation (AF) undergoing DC cardioversion will be enrolled, as will a control group of AF patients without HF matched for age, sex, and B-Blocker or amiodarone use. Patients will receive ibutilide 1.0 mg intravenously over 10 minutes. ECGs and venous blood samples will be taken before ibutilide administration and at specific times for 48 hours following the end of infusion. QT intervals will be measured and corrected using several methods and serum ibutilide concentrations will be determined. Expected outcomes: 1) Patients with HF will have: Lower QT interval Ec50; Higher AUQCT; Greater QT interval Emax, 2) Patients with LV dysfunction will have: Higher ibutilide Cmax; Reduced CL; Smaller Vd; Greater AUC; Longer half-life. This research will show that patients with HF have increased myocardial responsiveness to potassium channel inhibition and impaired ability to eliminate a heptically metabolized potassium channel blocking drug, and will have important implications regarding use of potassium channel blocking agents and for drug development.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000750-35
Application #
7606416
Study Section
Special Emphasis Panel (ZRR1-CR-8 (01))
Project Start
2006-12-01
Project End
2007-11-30
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
35
Fiscal Year
2007
Total Cost
$170
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Patel, Yash R; Kirkman, M Sue; Considine, Robert V et al. (2017) Retinopathy predicts progression of fasting plasma glucose: An Early Diabetes Intervention Program (EDIP) analysis. J Diabetes Complications 31:605-610
Robarge, Jason D; Metzger, Ingrid F; Lu, Jessica et al. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrob Agents Chemother 61:
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419

Showing the most recent 10 out of 767 publications